|
Integrin Regulation of Cancer Progression Through Alternative mRNA Splicing and Nonsense-Medidated Decay (NMD)
|
2R01CA129637-06A1
|
$375,250
|
|
DIPERSIO, C. MICHAEL
|
ALBANY MEDICAL COLLEGE
|
|
Signal transduction regulating tumor cell dissemination
|
2R01CA150344-28
|
$396,625
|
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Roles of formins in breast cancer invasion
|
1R21CA205262-01
|
$181,613
|
|
HODGSON, LOUIS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
EASTERN COOPERATIVE ONCOLOGY GROUP
|
3U10CA014958-38S1
|
$144,167
|
$1,442
|
Sparano, Joseph
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
The role of macroH2A variants in cancer and senescence
|
5R01CA155232-06
|
$346,525
|
|
GAMBLE, MATTHEW
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Deciphering the Tissue Specificity of MEN1 Related Tumorigenesis
|
5R01CA170911-06
|
$346,525
|
|
LIBUTTI, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Par1-substrates responsible for CagA-mediated pathogenesis of Helicobacter pylori
|
5R01CA160790-06
|
$522,889
|
|
MUESCH, ANNE
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Inhaled DNA demethylating therapy for lung cancer and bronchial premalignancy
|
5R01CA154755-07
|
$442,325
|
|
PEREZ-SOLER, ROMAN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Nemours Community Clinical Oncology Program
|
1U10CA176879-01
|
$558,366
|
$33,502
|
SANDLER, ERIC
|
ALFRED I. DU PONT HOSP FOR CHILDREN
|
|
Advancing Dissemination and Implementation Research on Walking and Walkability: Developing Research Priorities
|
1R13CA203386-01
|
$10,000
|
|
KRAFT, KATHERINE
|
AMERICA WALKS, INC.
|
|
Radiation Therapy Oncology Group
|
5U10CA021661-37
|
$14,566,378
|
$145,664
|
Curran, Walter
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
American College of Radiology Imaging Network
|
3U10CA080098-14S2
|
$5,146,722
|
$51,467
|
Schnall, Mitchell
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
Combinatorial Inactivation of ERBB Receptors in Breast Cancer using Therapeutic Stapled Peptides
|
1R41CA203353-01
|
$300,000
|
|
CAMENISCH, TODD
|
ARIZONA CANCER THERAPEUTICS, LLC
|
|
Stand and Move at Work: A Group-Randomized Trial
|
5R01CA198971-02
|
$617,374
|
|
BUMAN, MATTHEW
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Novel Androgen Receptor Degraders to Treat Castration-Resistant Prostate Cancer
|
1R44CA203199-01
|
$648,400
|
|
WINKLER, JAMES
|
ARVINAS, INC.
|
|
Development of cell-free DNA assays for HCC screening and liquid biopsy
|
1R01CA202769-01
|
$432,900
|
|
SU, YING-HSIU
|
BARUCH S. BLUMBERG INSTITUTE
|
|
Bay Area Tumor Institute CCOP
|
5U10CA045461-24
|
$486,165
|
$14,585
|
Feusner, James
|
BAY AREA TUMOR INSTITUTE
|
|
A New Lab Based Algorithm for HCC Surveillance in Patients with Cirrhosis
|
5R01CA190776-02
|
$636,299
|
|
EL-SERAG, HASHEM
|
BAYLOR COLLEGE OF MEDICINE
|
|
Novel targets that are deregulated by loss of PTEN
|
5R01CA108614-10
|
$288,103
|
|
JOHNSON, DEBORAH
|
BAYLOR COLLEGE OF MEDICINE
|
|
The cell of origin of breast cancer metastasis
|
1R21CA202227-01
|
$172,369
|
|
LI, YI
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQD-5) Patient derived orthotopic xenograft models for drug response prediction
|
5R01CA185402-03
|
$322,828
|
|
LI, XIONAN
|
BAYLOR COLLEGE OF MEDICINE
|
|
In Vivo Drug Testing of Pediatric CNS Tumors Using Patient Derived Orthotopic Xenograft Models
|
5U01CA199288-02
|
$578,693
|
|
LI, XIONAN
|
BAYLOR COLLEGE OF MEDICINE
|
|
The Role of Mitochondrial Heterogeneity in Pyruvate Flux in Prostate Cancer Progression
|
1R21CA205257-01
|
$206,843
|
|
MCGUIRE, SEAN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Metabolic Regulation in Leukemia-Initatiating Cells
|
5R01CA193235-02
|
$462,191
|
|
NAKADA, DAISUKE
|
BAYLOR COLLEGE OF MEDICINE
|
|
Prospective Identification of Translational Regulators in EMT
|
5R21CA185769-02
|
$172,369
|
|
NEILSON, JOEL
|
BAYLOR COLLEGE OF MEDICINE
|
|
The Notch Signaling in Prostate Homeostasis and Carcinogenesis
|
5R01CA190378-02
|
$362,569
|
|
XIN, LI
|
BAYLOR COLLEGE OF MEDICINE
|
|
NCOA6, A Novel Tumor Suppressor of Endometrial Cancer
|
1R01CA193455-01A1
|
$374,023
|
|
XU, JIANMING
|
BAYLOR COLLEGE OF MEDICINE
|
|
Spindle Assembly Checkpoint, Chromosome Stability, and Cancer
|
4R01CA122623-09
|
$314,977
|
|
ZHANG, PUMIN
|
BAYLOR COLLEGE OF MEDICINE
|
|
METHYLATION BIOMARKER DEVELOPMENT FOR NONINVASIVE DETECTION OF COLORECTAL CANCER
|
5R01CA181572-03
|
$315,983
|
|
GOEL, AJAY
|
BAYLOR RESEARCH INSTITUTE
|
|
Development of microRNA Biomarkers For Noninvasive Detection of Colorectal Cancer
|
5R01CA184792-02
|
$359,828
|
|
GOEL, AJAY
|
BAYLOR RESEARCH INSTITUTE
|
|
Stem Cell/Nanoparticle Constructs for Targeted Ovarian Cancer Therapy
|
5R01CA197359-02
|
$388,875
|
|
BERLIN, JACOB
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Integrating Palliative Oncology Care into Doctor of Nursing Practice Programs
|
4R25CA171960-04
|
$305,908
|
|
FERRELL, BETTY
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Training Healthcare Professionals to Implement Biopsychosocial Screening
|
4R25CA174444-04
|
$305,617
|
|
LOSCALZO, MATTHEW
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Targeted Chemoprevention of Breast Cancer: From the Bench to Clinical Testing
|
5R01CA158668-06
|
$335,466
|
|
SEEWALDT, VICTORIA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Novel AHCT Regimen for Advanced Hodgkin Lymphoma using Y-90 anti-CD25 with BEAM
|
5R21CA185875-02
|
$174,122
|
|
SMITH, EILEEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Hyperglycemia-induced DNA damage as a driver of genomic instability
|
4R01CA176611-04
|
$393,639
|
|
TERMINI, JOHN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Mechanism of chemoresistance mediated by TGF-beta
|
4R01CA163586-05
|
|
|
WANG, SHIZHEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Molecular epidemiology of non-Hodgkin lymphoma prognosis and prevention
|
4R01CA166219-05
|
$561,758
|
|
WANG, SOPHIA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Molecular Mechanisms of BRCA1-Dependent DNA Damage Response and Tumorogenesis
|
5R01CA132755-09
|
$382,500
|
|
YU, XIAOCHUN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Virginia Mason Community Clinical Oncology Program
|
5U10CA035192-29
|
$612,504
|
$6,125
|
Nichols, Craig
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
Control of tumor growth and metastasis by the cytokine TSLP
|
5R01CA182783-03
|
$362,503
|
|
ZIEGLER, STEVEN
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
Computational pathology to predict breast cancer risk in benign breast disease
|
5R21CA187642-02
|
$191,441
|
|
BECK, ANDREW
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Mechanism of Acquired Resistance to VEGF-R Antagonists in RCC
|
5K08CA138900-04
|
$169,560
|
$169,560
|
BHATT, RUPAL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Combating Resistance to Antiangiogenic Therapy in Renal Cell Carcinoma
|
5R01CA196996-02
|
$398,025
|
$398,025
|
BHATT, RUPAL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Eastern Cooperative Oncology Group
|
3U10CA080775-14S1
|
$43,980
|
$440
|
BUBLEY, GLENN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Akt isoform-specific signaling in breast cancer metastasis
|
5R00CA157945-05
|
$241,629
|
|
CHIN, YUET MING REBECCA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Targeting the PI3-Kinase/Akt Pathway for the Therapy of Renal Cell Carcinoma
|
5K08CA142890-05
|
$169,400
|
$169,400
|
Cho, Daniel
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
The Tumor Antigens Tn and SialylTn in Human Colorectal Carcinoma
|
5U01CA168930-06
|
$371,065
|
|
CUMMINGS, RICHARD
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Modeling KRAS genetic heterogeneity in mouse models
|
1R01CA195744-01A1
|
$535,118
|
|
HAIGIS, KEVIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Basic and Translational studies of Ras-mutant colorectal cancer
|
5R01CA178017-03
|
$359,556
|
|
HAIGIS, KEVIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
Total relevant funding to Kidney Cancer for this search: $53,778,509
|